CETP Inhibitors reveals abnormal lipid metabolism of coronary heart disease, it has been big improved in recent decades in the field of coronary heart disease. Cholesteryl ester transfer protein (CETP) mediated by lipid transport through the different lipoproteins, regulate lipid metabolism. Inhibit the transport activity of CETP can increase high-density lipoprotein cholesterol (HDL-c) levels,  therefore Cetp Inhibitors were expected to become a new type of treatment for cardiovascular diseases and new research directions.
Lipid metabolism is an important risk factor of atherosclerosis and coronary heart disease , lipid lowering drugs  regulate lipid metabolism, reduce blood lipid levels, thereby reducing the incidence of cardiovascular disease,  Torcetrapib has been entered the clinical trials which is the first investment in clinical research of CETP Inhibitors. In early small scale clinical studies found that use Torcetrapib combined with statins, can significantly improve fat HDL-C levels in patients with hyperlipidemia, further reducing LDL-C levels at the same time.
However, when a large-scale Phase Ⅲ clinical trials was earlier terminated by safety supervision institutions in the following year. although the research was stopped, it was not meaning that CETP inhibitor is harmful for atherosclerosis, CETP inhibitor is still have a relatively development prospects.
  It is also shows that a new drugs developed is very complexity and difficulty. But in the near future  more clinical evidence appears and clinical studies of CETP inhibitors develop, will have a profound impact on the future of clinical treatment of blood lipids.


Conbottpharm could give you: 
1. Best quality in your requirement 
2. Competitive price in China market 
3. Mature Technical support 
4. Professional logistic support 
All we want is win-win business. Send yr. inquiries, you will get it!